The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer

Reply to “The use of national datasets to evaluate outcomes for invasive lobular carcinoma”

“…They further support the implementation of the TAILORx and RxPONDER recommendations for patients with ILC and show an OS advantage associated with CT in high‐RS patients with ILC and especially in those with N1 disease. Although a selection bias and a lack of cancer‐specific outcomes are inherent to our NCDB analysis, similar to the study by Jenkins et al 5 that Marmor et al support, we believe that it can serve as a valuable resource for shared decision‐making.…”

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

“…Several messages can however be drawn from these studies. Firstly, the proportion of patients classified as 'high risk' varies significantly according to the test used, ranging between 1% and 2% for the RS® using the RS >30 cut-off (or w8% when considering the RS >25 cut-off), 39,128,131,[140][141][142][143][144][145][146][147][148] 11% and 28% for MammaP-rint®, 40,[149][150][151] 31% for the Prosigna-PAM50 ROR score, 152 37% for EPClin 153 and 46% for The Breast Cancer Index (BCI) Risk of Recurrence. 154 A higher proportion of 'highrisk' patients were consistently identified in non-classic ILC compared to classic ILC, both when considering the RS® 39 and MammaPrint®.…”

“…MammaPrint possibly useful for both NST and ILC 40,150 Similar prevalence and type of ESR1 muta 31,181…”

The use of national datasets to evaluate outcomes for invasive lobular carcinoma

“…Kizy et al 2 also reported that the RS is prognostic for breast cancer–specific survival (BCSS) for patients with high‐risk ILC in the Surveillance, Epidemiology, and End Results (SEER) database. Additionally, Jenkins et al 3 reported that the 70‐gene signature test was prognostic for OS for patients with ILC in the NCDB.…”

“…Kizy et al 2 also reported that the RS is prognostic for breast cancer-specific survival (BCSS) for patients with high-risk ILC in the Surveillance, Epidemiology, and End Results (SEER) database. Additionally, Jenkins et al 3 reported that the 70-gene signature test was prognostic for OS for patients with ILC in the NCDB.However, Weiser et al 1 also reported that among patients with high-risk-RS ILC, adjuvant chemotherapy was associated with improved OS. These findings are in contrast to other reports.…”